CKD

Does aldosterone synthase inhibition prevent kidney disease progression, heart failure or cardiovascular death?

Protocol Name: Does aldosterone synthase inhibition prevent kidney disease progression, heart failure or cardiovascular death? Sponsor: Boehringer Ingelheim Indication: CKD GFR: 20-90 DETAILS >

Does aldosterone synthase inhibition prevent kidney disease progression, heart failure or cardiovascular death? Read More »

A Phase III Study to Investigate the Efficacy and Safety of Baxdrostat in Combination with Dapagliflozin on CKD Progression in Participants with CKD and High Blood Pressure.

Protocol Name: A Phase III Study to Investigate the Efficacy and Safety of Baxdrostat in Combination with Dapagliflozin on CKD Progression in Participants with CKD and High Blood Pressure. Sponsor: AstraZeneca Indication: CKD & HTN GFR: 30-89 Principal Investigator: Ankit Mehta, MD Location: Landry Center, 411 N. Washington Ave, Suite #6000, Dallas, TX 75246 DETAILS

A Phase III Study to Investigate the Efficacy and Safety of Baxdrostat in Combination with Dapagliflozin on CKD Progression in Participants with CKD and High Blood Pressure. Read More »